Brief: Mereo BioPharma Reports Full Year 2024 Financial Results And Provides Corporate Highlights
26/03/2025 11:40
March 26 (Reuters) - Mereo Biopharma Group PLC MAH0y.F: MEREO BIOPHARMA REPORTS FULL YEAR 2024 FINANCIAL RESULTS AND PROVIDES CORPORATE HIGHLIGHTS MEREO BIOPHARMA GROUP PLC - ORBIT PHASE 3 STUDY OF SETRUSUMAB PROGRESSING SECOND INTERIM ANALYSIS, EXPECTED MID-2025 Source text: ID:nGNX1sRwzc Further company coverage: [MAH0y.F] ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Mereo BioPharma
See all newsBrief: Sentynl Therapeutics And Mereo Biopharma Announce Option And License Agreement For Alvelestat In Alpha-1 Antitrypsin Deficiency-Associated Lung Disease
UK's Mereo BioPharma Q2 loss narrows on lower R&D spending
Brief: Mereo BioPharma Q2 Operating Income USD -7.03 Million
Brief: Mereo BioPharma Q1 Net Income USD -6.719 Million
Brief: Mereo BioPharma FY Revenue USD 500 Thousand Vs. IBES Estimate USD 520 Thousand